Sun, Aug 31, 2014, 2:24 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Synergy Pharmaceuticals, Inc. Message Board

  • herkyhawk00 herkyhawk00 Mar 11, 2014 10:47 AM Flag

    Why is SP-333 being used for OIC & not Plecanatide?

    Was hoping I could get some feedback with this. With the great results from plecanatide in a large phase II in patients with CIC, why not use Plecanatide also for OIC? Seems that with both Linzness and Amitiza being used for OIC, I am confused why Plecanatide isn't and SP-333 is?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • How does SP-333 differ from Plecanatide?
      SP-333 is similar to Synergy’s first GC-C agonist peptide, plecanatide, except that the N- and C-terminal amino acids have been altered to reduce the potential for proteolytic degradation in the gut.

      In English
      SP-333 is a modified version of Plecanatide. SP-333 will probably show results with even less diarrhea than Plecanatide. Why did Pfizer promote Celebrex and Bextra? This move will allow SGYP's GC-C drugs to gain more marketshare and make more $$. If SP-333 has less diarrhea due to it's modified structure, doesn't matter what the indications are, physicians will use it. Some of this I am speculating on, however, SP-333 is a modified Plecanatide and you can speculate the reasons behind it too.

3.90+0.12(+3.17%)Aug 29 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Burger King Worldwide, Inc.
NYSEFri, Aug 29, 2014 4:02 PM EDT
Avago Technologies Limited
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT